ConductScience.org, home

Paper41003140

Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection.

Alkhalifa AE and 4 others. J Pers Med, 2025. Cited by 40 papers, by iCite.

Cite this record

ConductScience Library. Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection. Papers, record 41003140. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41003140

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection.
PubMed
Journal
J Pers Med
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
40
iCite
Relative citation ratio, by iCite
12.52, provisional
iCite
Revised in PubMed
2025-09-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Alkhalifa AEAmer Ehttps://orcid.org/0000-0002-6872-4780
2Al Mokhlf AAbdulrahman
3Ali HHande
4Al-Ghraiybah NFNour Fhttps://orcid.org/0009-0007-7278-9134
5Syropoulou VVasiliki

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References123

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127025652The amyloid hypothesis of Alzheimer's disease at 25 years.EMBO Mol Med2016https://conductscience.org/library/papers/27025652PubMed
238692883[Mechanism of action and clinical trial results of Lecanemab (Leqembi® 200 ‍mg, 500 ‍mg for Intravenous Infusion), a novel treatment for Alzheimer's disease].Nihon Yakurigaku Zasshi2024https://conductscience.org/library/papers/38692883PubMed
338779110Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease.Innov Pharm2024https://conductscience.org/library/papers/38779110PubMed
427048170Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.Alzheimers Res Ther2016https://conductscience.org/library/papers/27048170PubMed
535379992New insights into the genetic etiology of Alzheimer's disease and related dementias.Nat Genet2022https://conductscience.org/library/papers/35379992PubMed
637183523The amyloid cascade hypothesis: an updated critical review.Brain2023https://conductscience.org/library/papers/37183523PubMed
729653606NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.Alzheimers Dement2018https://conductscience.org/library/papers/29653606PubMed
814755729Clinical manifestations of cerebral amyloid angiopathy-related inflammation.Ann Neurol2004https://conductscience.org/library/papers/14755729PubMed
928229126Assessing quality of life in Alzheimer's disease: Implications for clinical trials.Alzheimers Dement (Amst)2017https://conductscience.org/library/papers/28229126PubMed
1035953274Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice.AJNR Am J Neuroradiol2022https://conductscience.org/library/papers/35953274PubMed
1119679070The role of apolipoprotein E in Alzheimer's disease.Neuron2009https://conductscience.org/library/papers/19679070PubMed
1232698317Monoclonal Antibodies in Cancer Therapy.Antibodies (Basel)2020https://conductscience.org/library/papers/32698317PubMed
131172191Continuous cultures of fused cells secreting antibody of predefined specificity.Nature1975https://conductscience.org/library/papers/1172191PubMed
1437955845Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease.BioDrugs2024https://conductscience.org/library/papers/37955845PubMed
1536835161Alzheimer's Disease: An Updated Overview of Its Genetics.Int J Mol Sci2023https://conductscience.org/library/papers/36835161PubMed
1611528419The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation.Nat Neurosci2001https://conductscience.org/library/papers/11528419PubMed
1740327104FDA vs. EMA: evaluating donanemab and the global debate on accelerated approvals.J Neurol2025https://conductscience.org/library/papers/40327104PubMed
1840155270Donanemab: Appropriate use recommendations.J Prev Alzheimers Dis2025https://conductscience.org/library/papers/40155270PubMed
1929686315Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.Sci Rep2018https://conductscience.org/library/papers/29686315PubMed
2034930757Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.BMJ2021https://conductscience.org/library/papers/34930757PubMed

See all 123 referencesDownload CSV of references

Cited by36

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 40 citations.

PMIDTitleJournalYearIn PapersSource
42923488Protein glycosylation and glycation in Alzheimer's disease: mechanisms, crosstalk, and therapeutic perspectives.Front Neurosci2026https://conductscience.org/library/papers/42923488PubMed
42909551Metabolic Dyshomeostasis, neuroinflammation, and glymphatic clearance deficits as convergent drivers of Alzheimer's disease: an exposome-based conceptual framework for prevention.Metab Brain Dis2026https://conductscience.org/library/papers/42909551PubMed
42890501
Effects of West Nile Virus on behavioral and cognitive performance, circadian body temperatures, cortical Aβ and p-tau pathology, and immune measures in human apoE and human amyloid precursor protein NL-G-F/human apoE mice.
Front Immunol2026https://conductscience.org/library/papers/42890501PubMed
42889352CD8+ t cell-mediated regulation of synaptic integrity in Alzheimer's disease.Front Immunol2026https://conductscience.org/library/papers/42889352PubMed
42884722Multidimensional Neuroprotective Effects of Combined Ubisol-Q10 and Ashwagandha (Withania somnifera) in Male and Female 5XFAD Mice.Nutrients2026https://conductscience.org/library/papers/42884722PubMed
42873408"Morphological, Functional, and Molecular Progression of Blood-Brain Barrier Dysfunction in Alzheimer's Disease".J Mol Neurosci2026https://conductscience.org/library/papers/42873408PubMed
42850455Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer's Disease: an Italian RAND/UCLA consensus.Neurol Sci2026https://conductscience.org/library/papers/42850455PubMed
42801246Alzheimer's Disease: From Molecular Pathogenesis to Disease-Modifying Therapies and Clinical Implementation in Aging Populations.Clin Interv Aging2026https://conductscience.org/library/papers/42801246PubMed
42796561Small-Molecule NANT Therapeutics Targeting the Brain-Immune Axis in Alzheimer's Disease: Mechanisms, Clinical Progress, and Translational Challenges.Molecules2026https://conductscience.org/library/papers/42796561PubMed
42750195Operationalizing Alzheimer's disease trials in the era of targeted therapies.Alzheimers Dement2026https://conductscience.org/library/papers/42750195PubMed
42739787Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella Review.J Clin Med2026https://conductscience.org/library/papers/42739787PubMed
42725220Before the bolus: why anti-amyloid therapy must become part of every stroke code.Ann Med Surg (Lond)2026https://conductscience.org/library/papers/42725220PubMed
42654386Beyond Amyloid: Systemic and Brain Frailty as Determinants of Response to Anti-Amyloid Therapy in Alzheimer's Disease-A Conceptual Review.Medicina (Kaunas)2026https://conductscience.org/library/papers/42654386PubMed
42627617The neuroimmune network in Alzheimer's and Parkinson's diseases: from mechanistic insights to biomarker-guided immunotherapies and clinical translation.Inflammopharmacology2026https://conductscience.org/library/papers/42627617PubMed
42588092Gut Microbiome Changes in Preclinical Alzheimer's Disease.Nutrients2026https://conductscience.org/library/papers/42588092PubMed
42573852Towards Structural Restoration: Epigenetic Reprogramming and Direct Astrocyte-to-Neuron Lineage Conversion as Next-Generation Regenerative Neurotherapeutics.Mol Neurobiol2026https://conductscience.org/library/papers/42573852PubMed
42524328Pharmacodynamic and stage-dependent therapeutic efficacy of SFRP1 neutralization in a mouse model of Alzheimer's disease.Alzheimers Dement (N Y)2026https://conductscience.org/library/papers/42524328PubMed
42512081Rodent Models of Alzheimer's Disease: Bridging the Translational Gap Through Systems-Level Integration.Biomedicines2026https://conductscience.org/library/papers/42512081PubMed
42453713Alzheimer's disease: A comprehensive review of epidemiology, pathophysiology, diagnosis, and treatment.AIMS Neurosci2026https://conductscience.org/library/papers/42453713PubMed
42440728Reprogramming lipid metabolism for cognitive restoration in Alzheimer's via PLA2G4E.Alzheimers Dement (N Y)2026https://conductscience.org/library/papers/42440728PubMed

See all 36 cited byDownload CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41003140

GET https://conductscience.org/api/papers/v1/41003140/references?page=2